trending Market Intelligence /marketintelligence/en/news-insights/trending/sniadgonj8q30ugcbscbdq2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Neon Therapeutics discloses share count, price range for IPO

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Neon Therapeutics discloses share count, price range for IPO

Neon Therapeutics Inc. plans to sell 6,250,000 common shares in its IPO at a price between $15 and $17 apiece.

The clinical-stage immuno-oncology company has granted the underwriters an option to buy up to 937,500 additional shares.

Certain of the company's existing stockholders and their affiliated entities have shown an interest in buying up to $35.0 million of the company's shares.

Neon Therapeutics, which is engaged in developing neoantigen-targeted therapies for cancers in the U.S., has applied to list its common stock on the Nasdaq Global Market under the symbol NTGN.

At an offering price of $16 per share, the company expects net proceeds of about $89.7 million, or about $103.6 million if the underwriters fully exercise their overallotment option.

The Cambridge, Mass.-based biotechnology company plans to use the net proceeds along with existing cash, cash equivalents and marketable securities and will use $40.0 million of the funds for the ongoing clinical development of its personal neoantigen vaccine NEO-PV-01.

About $40.0 million will be used to fund the company's preclinical programs and research activities, including costs related to the planned clinical development of its personal neoantigen T cell therapy NEO-PTC-01, among other things.

The remaining proceeds are expected to fund capital expenditures, working capital and other general corporate purposes.

Morgan Stanley & Co. LLC, Merrill Lynch Pierce Fenner & Smith Inc., Mizuho Securities USA LLC and Oppenheimer & Co. Inc. are acting as underwriters in the IPO.